Small for Gestational Age Clinical Trial
Official title:
Effect of Insulin Sensitization on Insulin Like Growth Factor-1 Responses to Growth Hormone Treatment in Children Born Small for Gestational Age
This study is aimed to determine if Metformin treatment in children born small for gestational age (SGA) who are being treated with Growth Hormone (GH) for short stature improves the response to GH by producing greater concentrations of Insulin-like growth factor -1 (IGF-1) in the blood.
Growth hormone treatment (GH) is recommended in children born small for gestational age
(SGA) who fail to catch-up. SGA is a heterogeneous condition as reflected in the varied
response to GH treatment. Variable generation and resistance to Insulin-like growth factor-1
(IGF-1), the most important circulating mediator of GH action may underpin this
heterogeneity. An association between the variants in the genes related to lower insulin
sensitivity and reduced IGF-1 and growth response to GH therapy in SGA children have been
reported recently. The hypothesis of this study is that insulin sensitivity may be causally
linked to the response to GH therapy, and adjuvant therapy with an insulin sensitizer may
improve IGF-1 generation, decrease IGF-I resistance and optimise growth response.
To explore this hypothesis, this study aims to determine the effects of insulin
sensitization using Metformin as an adjuvant to a fixed dose GH therapy for 6 months in
short SGA children. The patients will be short SGA children between age 4 -10 years and
identified from three paediatric endocrine units in Denmark, Ireland and the United Kingdom.
In this mechanistic study 24 subjects starting GH treatment will be randomised in a 1:1
ratio to adjunctive Metformin or placebo for 6 months and followed-up for another 6months.
The participants will receive GH treatment for the entire duration of the study (12 months)
and will undergo an oral glucose tolerance test and dual-energy x-ray absorptiometry scan to
determine glucose metabolism and body fat mass respectively at baseline and 6 months, and
will have 3 monthly measurements of height, weight and skinfold thickness. The primary
outcome will be the area under the curve of IGF-1 levels measured at 0, 1, 3 and 6 months.
Secondary outcomes will include changes in insulin sensitivity, height, body fat mass and
safety measures at 6 and 12 months.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Recruiting |
NCT03662178 -
Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
|
||
Completed |
NCT01697644 -
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation
|
Phase 4 | |
Completed |
NCT01110928 -
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
|
||
Completed |
NCT02280031 -
Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.
|
Phase 2 | |
Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
Completed |
NCT00184756 -
Efficacy on Height in SGA Children Treated With Growth Hormone
|
Phase 3 | |
Completed |
NCT01578135 -
French National Registry of Children Born Small for Gestational Age Treated With Somatropin
|
||
Recruiting |
NCT05603936 -
Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
|
||
Completed |
NCT00925925 -
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
|
N/A | |
Completed |
NCT00738205 -
Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector
|
N/A | |
Completed |
NCT00557336 -
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
|
Phase 3 | |
Completed |
NCT00371657 -
Maternal Obesity and Small for Gestational Age Infants
|
N/A | |
Completed |
NCT00519844 -
Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction
|
Phase 4 | |
Completed |
NCT00184717 -
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
|
Phase 3 | |
Recruiting |
NCT01604395 -
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
|
||
Terminated |
NCT00597480 -
Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)
|
Phase 4 | |
Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
Recruiting |
NCT02964793 -
Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants
|
N/A | |
Recruiting |
NCT04798690 -
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
|